A Phase 3 interventional study of adalimumab and methotrexate in Early Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 68 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-15.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 26th largest by enrollment, is one of 4 that started in 2010, is one of 36 in phase 3, and was the 37th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 395 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 11th largest by enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2010, is one of 11 in phase 3, and was the 19th registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must meet the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks
Biological: adalimumab · Drug: methotrexate
5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
Biological: adalimumab · Drug: methotrexate
10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
Biological: adalimumab · Drug: methotrexate
MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks
Biological: adalimumab · Drug: methotrexate
Pre-filled syringe every other week
Also known as: Humira
weekly oral capsule dosing
Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26
Percentage of participants achieving low disease activity as defined by a clinical response (DAS28\[CRP\] \< 3.2). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
Time frame: Week 26
Percentage of Participants With DAS28(CRP) Remission at Week 26
Disease remission was defined as a disease activity score, based on CRP, for 28 joints that was \< 2.6 (DAS28\[CRP\] \< 2.6). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10.
Time frame: Week 26
Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26
Response, as defined by ACR 20 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).
Time frame: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26
Response, as defined by ACR 50 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).
Time frame: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26
Response, as defined by ACR 70 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).
Time frame: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26
Response, as defined by ACR 90 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 90% improvement in tender joint count; ≥ 90% improvement in swollen joint count; and ≥ 90% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).
Time frame: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26
Response, as defined by ACR 100 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 100% improvement in tender joint count; ≥ 100% improvement in swollen joint count; and ≥ 100% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).
Time frame: Baseline, Week 26
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline in the overall score indicates improvement.
Time frame: Baseline, Week 26
Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 26
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from Baseline of ≥ 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline in the overall score indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26
The modified Total Sharp Score (mTSS) is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Time frame: Baseline, Week 26
Percentage of Participants With No Radiographic Progression at Week 26
"No radiographic progression" was defined as a change from Baseline in modified Total Sharp Score (mTSS) at Week 26 of ≤ 0.5. mTSS is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Time frame: Baseline, Week 26
Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26
SDAI is a measure of disease activity derived as follows: SDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) + CRP (mg/dL), where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 \[none\] to 10 \[severe\]), and CRP is C-reactive protein measured in mg/dL. SDAI total score = 0 to 86. SDAI ≤ 3.3 indicates disease remission, \> 3.4 to 11 = low disease activity, \> 11 to 26 = moderate disease activity, and \> 26 = high disease activity.
Time frame: Week 26
Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26
CDAI is a measure of disease activity derived as follows: CDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 \[none\] to 10 \[severe\]). CDAI total score = 0 to 76. CDAI ≤ 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity.
Time frame: Week 26
| Milestone | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Started | 98 | 100 | 99 | 98 |
| Completed | 83 | 93 | 93 | 89 |
| Not completed | 15 | 7 | 6 | 9 |
| Withdrew: Adverse event | 3 | 0 | 2 | 3 |
| Withdrew: Withdrawal by subject | 7 | 5 | 2 | 3 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 1 |
| Withdrew: Other reason | 3 | 2 | 2 | 2 |
Percentage of participants achieving low disease activity as defined by a clinical response (DAS28\[CRP\] \< 3.2). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26 | 42.9 | 44.0 | 56.6 | 60.2 |
Disease remission was defined as a disease activity score, based on CRP, for 28 joints that was \< 2.6 (DAS28\[CRP\] \< 2.6). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10.
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With DAS28(CRP) Remission at Week 26 | 27.6 | 32.0 | 37.4 | 44.9 |
Response, as defined by ACR 20 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26 | 67.3 | 74.0 | 76.8 | 79.6 |
Response, as defined by ACR 50 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26 | 45.9 | 51.0 | 53.5 | 62.2 |
Response, as defined by ACR 70 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26 | 24.5 | 34.0 | 41.4 | 45.9 |
Response, as defined by ACR 90 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 90% improvement in tender joint count; ≥ 90% improvement in swollen joint count; and ≥ 90% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26 | 7.1 | 10.0 | 17.2 | 16.3 |
Response, as defined by ACR 100 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 100% improvement in tender joint count; ≥ 100% improvement in swollen joint count; and ≥ 100% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26 | 1.0 | 1.0 | 2.0 | 4.1 |
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline in the overall score indicates improvement.
| units on a scale | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26 | -0.72 ± 0.664 | -0.71 ± 0.717 | -0.78 ± 0.647 | -0.82 ± 0.698 |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from Baseline of ≥ 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline in the overall score indicates improvement.
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 26 | 68.4 | 70.0 | 73.7 | 77.6 |
The modified Total Sharp Score (mTSS) is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
| score on a scale | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26 | 0.9 ± 5.62 | 0.3 ± 1.92 | 0.4 ± 3.17 | 0.2 ± 2.22 |
"No radiographic progression" was defined as a change from Baseline in modified Total Sharp Score (mTSS) at Week 26 of ≤ 0.5. mTSS is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With No Radiographic Progression at Week 26 | 64.3 | 72.0 | 76.8 | 77.6 |
SDAI is a measure of disease activity derived as follows: SDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) + CRP (mg/dL), where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 \[none\] to 10 \[severe\]), and CRP is C-reactive protein measured in mg/dL. SDAI total score = 0 to 86. SDAI ≤ 3.3 indicates disease remission, \> 3.4 to 11 = low disease activity, \> 11 to 26 = moderate disease activity, and \> 26 = high disease activity.
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26 | 11.2 | 22.0 | 28.3 | 29.6 |
CDAI is a measure of disease activity derived as follows: CDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 \[none\] to 10 \[severe\]). CDAI total score = 0 to 76. CDAI ≤ 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity.
| percentage of participants | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26 | 12.2 | 22.0 | 29.3 | 27.6 |
Collected over Treatment-emergent adverse events and serious adverse events, defined as those that began after the first dose of study drug, but within 70 days after the last dose of study drug. Duration of treatment was 24 weeks for ADA and 25 weeks for MTX.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADA + 2.5 mg MTX | — | 5/98 (5.1%) | 24/98 (24.5%) |
| ADA + 5 mg MTX | — | 2/100 (2%) | 26/100 (26%) |
| ADA + 10 mg MTX | — | 3/99 (3%) | 34/99 (34.3%) |
| ADA + 20 mg MTX | — | 7/98 (7.1%) | 41/98 (41.8%) |
| Event | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 3/98 | 0/100 | 1/99 | 0/98 |
| ANAEMIABlood and lymphatic system disorders | 0/98 | 0/100 | 1/99 | 1/98 |
| ACUTE CORONARY SYNDROMECardiac disorders | 0/98 | 0/100 | 0/99 | 1/98 |
| ABDOMINAL PAINGastrointestinal disorders | 0/98 | 0/100 | 0/99 | 1/98 |
| COLITIS ULCERATIVEGastrointestinal disorders | 0/98 | 0/100 | 0/99 | 1/98 |
| INGUINAL HERNIAGastrointestinal disorders | 0/98 | 0/100 | 0/99 | 1/98 |
| ASTHENIAGeneral disorders | 1/98 | 0/100 | 0/99 | 0/98 |
| INTERVERTEBRAL DISC DEGENERATIONMusculoskeletal and connective tissue disorders | 0/98 | 0/100 | 0/99 | 1/98 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 1/98 | 0/100 | 0/99 | 0/98 |
| HYPERTENSIONVascular disorders | 0/98 | 0/100 | 0/99 | 1/98 |
| Event | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX |
|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 7/98 | 5/100 | 13/99 | 8/98 |
| NASOPHARYNGITISInfections and infestations | 3/98 | 6/100 | 6/99 | 11/98 |
| HEADACHENervous system disorders | 4/98 | 6/100 | 5/99 | 9/98 |
| ALOPECIASkin and subcutaneous tissue disorders | 1/98 | 5/100 | 6/99 | 8/98 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 6/98 | 2/100 | 3/99 | 0/98 |
| DIARRHOEAGastrointestinal disorders | 3/98 | 6/100 | 6/99 | 3/98 |
| FATIGUEGeneral disorders | 2/98 | 2/100 | 6/99 | 4/98 |
| DIZZINESSNervous system disorders | 4/98 | 0/100 | 6/99 | 4/98 |
| ABDOMINAL PAINGastrointestinal disorders | 0/98 | 0/100 | 1/99 | 5/98 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/98 | 2/100 | 3/99 | 5/98 |
| Age Continuous(years) | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX | Total |
|---|---|---|---|---|---|
| Mean | 52.0 ± 13.19 | 49.7 ± 13.14 | 52.1 ± 12.94 | 53.8 ± 14.41 | 51.9 ± 13.46 |
| Age, Customized(participants) | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX | Total |
|---|---|---|---|---|---|
| < 65 years | 84 | 89 | 85 | 77 | 335 |
| > 65 years | 14 | 11 | 14 | 21 | 60 |
| Sex: Female, Male(Participants) | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX | Total |
|---|---|---|---|---|---|
| Female | 70 | 78 | 78 | 74 | 300 |
| Male | 28 | 22 | 21 | 24 | 95 |
| 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP])(scores on a scale) | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX | Total |
|---|---|---|---|---|---|
| Mean | 6.10 ± 0.921 | 6.22 ± 0.943 | 5.86 ± 0.971 | 5.91 ± 1.014 | 6.02 ± 0.970 |
| Modified Total Sharp Score (mTSS)(score) | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX | Total |
|---|---|---|---|---|---|
| Mean | 9.79 ± 12.849 | 8.60 ± 8.912 | 10.76 ± 13.017 | 10.55 ± 12.852 | 9.92 ± 12.005 |
| Health Assessment Questionnaire - Disability Index (HAQ-DI)(units on a scale) | ADA + 2.5 mg MTX | ADA + 5 mg MTX | ADA + 10 mg MTX | ADA + 20 mg MTX | Total |
|---|---|---|---|---|---|
| Mean | 1.49 ± 0.737 | 1.57 ± 0.624 | 1.62 ± 0.667 | 1.58 ± 0.653 | 1.57 ± 0.670 |
The record gives a start of Oct 2010, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adalimumab · Methotrexate
AbbVie (prior sponsor, Abbott) →